Several presentations at the 46th World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease showed pharmacokinetic (PK) data for anti-tuberculosis (TB) drugs in children.

Good preliminary results from an observational trial of a 9-month regimen for multidrug-resistant (MDR) TB conducted in francophone Africa were presented at the 46th World Health Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease (The Union).

Lopinavir/ritonavir (LPV/r) dosed at 1:1 ratio in the presence of rifampicin (RIF) was not inferior to LPV/r 4:1 ratio without rifampicin in HIV positive children in an interim pharmacokinetics (PK) analysis presented at the 7th International Workshop on HIV Paediatrics.

Results from a survey presented at 45th Union World Conference on Lung Health reveal an urgent need for child appropriate formulations of second line TB drugs. [1]

Incidence of TB disease was highest in the first three months in children with HIV receiving antiretroviral treatment (ART) in the ARROW trial. [1]

Moxifloxacin concentrations were lower in children than adults according to pharmacokinetic (PK) data presented at the 45th Union World Conference on Lung Health. [1]

The South African Bedaquiline Clinical Access Programme showed good interim outcomes in people with drug resistant tuberculosis (DR-TB), according to data presented at the 45th Union Conference on Lung Health.

An analysis of treatment outcomes in HIV positive and negative people with drug resistant (DR) tuberculosis (TB) in Khayelitsha showed similar treatment success and long-term mortality in the presence of ART.

Children with tuberculosis (TB) are usually not infectious, so they are rarely considered to be a public health priority.

There are scant data for second-line TB drugs in children and there is very little to guide use of even first-line ones in neonates and infants with low birth weight.